Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB3909 + TQB3702 in Hematologic Malignancy
NCT06211751Phase 1Not yet recruiting
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Jan 2024
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TQB3909 and TQB3702 in hematologic malignancy and non-Hodgkin lymphoma (NHL), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoints: Dose limited toxicity at 104 weeks, Adverse events at 104 weeks and 2 more. Planned start Jan 2024; status: not yet recruiting.
02
Drugs
TQB3909TQB3702
03
Conditions
hematologic malignancynon-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT06211751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06211751.